Minneapolis-based HistoSonics’ agreement formalizes ongoing efforts to use GE Healthcare’s Logiq E10 Series ultrasound imaging platform to power the real-time visualization features of HistoSonics’ sonic beam liver therapy platform.
Under the agreement — and upon market authorization — HistoSonics will distribute GE Healthcare’s Logiq E10 Series on a one-to-one basis with its breakthrough liver therapy system, according to a news release.
HistoSonics designed its Edison system to use histotripsy to non-invasively destroy targeted liver tissue. Edison mechanically destroys and liquified targeted tissues at a sub-cellular level. The company said it plans to use GE Healthcare’s imaging platform to offer continuous visualization for key and unique elements of the histotripsy therapy procedure, including planning, monitoring and immediate post-treatment verification.
The agreement supports HistoSonics’ efforts to launch Edison, which leverages the company’s expertise along with GE Healthcare’s leading ultrasound technologies, digital infrastructure, data analytics and clinical decision support capabilities, the company said.
HistoSonics continues to enroll in its U.S. and European clinical trials evaluating the safety and efficacy of histotripsy for the destruction of targeted primary or metastatic liver tumors. The company received FDA breakthrough device designation for its technology, which remains investigational and not for sale.
“We are very excited to formalize our imaging partnership with GE Healthcare, which is a key part of bringing our transformative therapy platform, and an entirely new treatment option, to the clinic and to patients,” HistoSonics VP of R&D Josh Stopek said in the release. “We’ve developed a very collaborative relationship with GE Healthcare and look forward to expanding our efforts to realize the full potential of histotripsy across clinical applications, specialties, and care settings.”